Abstract:Abstract Purpose This study aimed at the development of a regulatory strategy for compliance of laboratory-developed tests (LDTs) with requirements of the Regulation (EU) 2017/746 (“EU-IVDR”) under consideration of international requirements for LDTs as established in major regulatory regions. Furthermore, it was analysed in how far elements of current LDT regulation could qualify for an internationally harmonised concept ensuring quality, safety and performance of LDTs. Methods A review of regulatory literature including legislation as well as guidance documents was performed. The regulatory strategy was adapted from international guidance concepts used for commercially marketed IVD. It was then applied to the example of a large medical laboratory in the EU. A high-level comparison was conducted to identify gaps and matches between the different international regulatory requirements for LDTs. Results A four-step strategy for compliance of LDTs with the EU IVDR was implemented in an exemplary medical laboratory. On the basis of an internationally used LDT definition, LDTs constitute nearly 50% of the total IVD devices used in the laboratory. While an ISO 15189-compliant QMS is a major component, it should be accompanied by the application of appropriate processes for risk management, performance evaluation and continuous monitoring of LDTs. At least six criteria represent common characteristics of a potential, internationally convergent concept for the regulation/standardization of LDTs. Conclusions This study confirms the impact of LDTs for individualized and innovative medical laboratory testing. Prerequisites for LDT use as especially given by the IVDR and missing interpretation in the EU with regard to the scope of LDT definition, the application of standards and the extent of documentation for LDTs currently lead to uncertainties for both laboratories and regulatory bodies responsible for LDT oversight. The characteristics identified as common criteria for ensuring quality, safety and performance of LDTs may be considered as central elements of future international consensus guidance.

Current situation in laboratory developed tests supervision

[Refined Management of the Second Class Warehouse and Cost-benefit Analysis for In-vitro Diagnostic Reagent].

The Current Status and Future Prospects of Laboratory Biomarkers in the Diagnosis of Liver Cancer

FDA's proposed rule for the regulation of laboratory-developed tests

The Future of Laboratory-Developed Tests in Hemostasis Laboratories

Laboratory-Developed Tests: Design of a Regulatory Strategy in Compliance with the International State-of-the-Art and the Regulation (EU) 2017/746 (EU IVDR [In Vitro Diagnostic Medical Device Regulation])

Metabolomic Laboratory-Developed Tests: Current Status and Perspectives

The Quality of POCT Ensured by the Hospital's Internal Management

Public Perspectives on Direct-to-Consumer Testing Oversight

The FDA’s Proposed Rule on Laboratory-Developed Tests: Impacts on Clinical Laboratory Testing and Patient Care

Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests

[Analysis of problems and management of in vitro diagnostic reagent clinical trials in medical laboratory]

The current situation and development of medical device testing institutes in China

Pondering on the Development of Molecular Diagnostics in China

Supervision System of AI-based Software As a Medical Device

License requirement of medical technicians and technologists in the United States: implication for clinical laboratorians in China

ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation

The Current Problems of Regulation of Medical Devices and Countermeasures

The new IVD Regulation 2017/746: a case study at a large university hospital laboratory in Belgium demonstrates the need for clarification on the degrees of freedom laboratories have to use lab-developed tests to improve patient care

Patient safety and healthcare quality of U.S. laboratory developed tests (LDTs) in the AI/ML era of precision medicine

Progression in Point-of-Care Testing for Tuberculosis